ASE · Financial Statements

NanoViricides, Inc. (NNVC) Revenue, Earnings & Financial Statements

$1.17 ASE: NNVC Market Cap $29.87M

Data as of Nov 17, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

NanoViricides, Inc. most recently reported annual revenue of $0, a net loss of $8.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

NanoViricides, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $8.0M.

Income Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Revenue$0$0$0$0$0$0$0$0$0$0
Operating Expenses$10.0M$9.0M$9.0M$8.0M$9.0M$8.0M$9.0M$9.0M$10.0M$8.0M
Operating Profit−$10.0M−$9.0M−$9.0M−$8.0M−$9.0M−$8.0M−$9.0M−$9.0M−$10.0M−$8.0M
Other Income−$1.0M$1.0M$0−$5.0M$0$0$0$0$0$0
Interest$2.0M$1.0M$0$0$0$0$0$0$0$0
Depreciation$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax−$10.0M−$9.0M−$8.0M−$13.0M−$9.0M−$8.0M−$9.0M−$8.0M−$9.0M−$8.0M
Tax rate (%)0.0%0.0%2.1%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$10.0M−$9.0M−$8.0M−$13.0M−$9.0M−$8.0M−$9.0M−$8.0M−$9.0M−$8.0M
EPS−$3.43−$2.64−$2.30−$2.39−$0.81−$0.70−$0.74−$0.70−$0.63−$0.41

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$2.0M$2.0M$2.0M$2.0M$3.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M
Operating Profit−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M−$2.0M
EPS−$0.17−$0.18−$0.16−$0.20−$0.23−$0.14−$0.14−$0.13−$0.10−$0.11−$0.09−$0.11

Over the 10 years reported for NanoViricides, Inc., borrowings decreased from $4.0M in 2017 to $0 in 2026, cash stood at $3.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.00 times.

Balance Sheet — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Total Assets$27.0M$19.0M$13.0M$24.0M$30.0M$23.0M$17.0M$13.0M$9.0M$10.0M
Current Assets$15.0M$7.0M$3.0M$14.0M$21.0M$14.0M$8.0M$5.0M$2.0M$3.0M
Cash$15.0M$7.0M$3.0M$14.0M$21.0M$14.0M$8.0M$5.0M$2.0M$3.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$0
Fixed Assets$11.0M$11.0M$10.0M$10.0M$9.0M$9.0M$8.0M$8.0M$7.0M$6.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$7.0M$1.0M$3.0M$2.0M$0$0$2.0M$1.0M$1.0M$1.0M
Current Liabilities$5.0M$1.0M$3.0M$2.0M$0$0$1.0M$1.0M$1.0M$1.0M
Borrowings$4.0M$0$0$1.0M$0$0$0$0$0$0
Other Liabilities$3.0M$1.0M$3.0M$1.0M$0$0$2.0M$1.0M$1.0M$1.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$20.0M$18.0M$11.0M$22.0M$30.0M$23.0M$15.0M$11.0M$8.0M$9.0M

For NanoViricides, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $7.78T; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Operating Cash Flow−$8.0M−$8.0M−$7.0M−$7.0M−$8.0M−$6.0M−$6.0M−$6.0M−$8.0M−$7.70T
Investing Cash Flow$0$0$0$0$0−$1.0M$0$0$0−$168.6B
Financing Cash Flow$0−$5.0M$0$0$0$0$0$0$0$9.02T
Net Cash Flow−$9.0M−$8.0M−$5.0M$11.0M$7.0M−$6.0M−$6.0M−$3.0M−$3.0M$1.24T
Free Cash Flow−$8.0M−$8.0M−$7.0M−$7.0M−$8.0M−$6.0M−$6.0M−$6.0M−$9.0M−$7.78T

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-4.37
FCF Yield8766261.02%
Quick Ratio2.66
Interest Coverage—
Return 1Y-8.89%
Return 3Y-8.21%
Return 5Y-70.45%

NanoViricides, Inc. (NNVC) financials — frequently asked questions

What is NanoViricides, Inc.'s annual revenue?

NanoViricides, Inc. (NNVC) reported annual revenue of $0 in its most recent fiscal year.

What is NanoViricides, Inc.'s net profit?

NanoViricides, Inc. (NNVC) reported a net loss of $8.0M in its most recent fiscal year.

What is NNVC EV/EBITDA?

NanoViricides, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -4.37. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
NNVC Overview NNVC Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.